Sarepta Therapeutics Inc Clinical Update: Study SRP-9001-103: 12-Week Expression and Safety Data Using Commercially Representative Material - Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Aaron Zachary Welch - Guggenheim Securities, LLC, Research Division - Analyst : This is Aaron on for Debjit. So I just have a question about when making comparisons with studies in Becker's patients from 2016, how different are the methods used to quantify dystrophin compared with the current method that Sarepta uses? And would it mean that earlier studies are overestimated or underestimated?

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : I also like to add congratulations on the results. I know it's a little hard to compare, but would you say that the commercial produced

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : And congrats on the data. So I was wondering, could you tell us what the 102 and the other data you collected tells you about the expression threshold for functional improvement? And then as you look at these 11 commercial patients, just how many of them were above this level? And then just on timing, could you just give us a bit more granular when we should expect the Phase III start first patient dose you anticipate your enrollment timing, et cetera?